

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived mouse Lysosomal alpha-Glucosidase protein
Glu70-Ser953 with a N-terminal 6-His tag
Accession # P70699.2

N-terminal Sequence Analysis His

Predicted Molecular Mass 99 kDa

SPECIFICATIONS

SDS-PAGE 97-107 kDa, under reducing conditions

Activity Measured by its ability to release glucose from starch.
The specific activity is >5000 pmol/min/μg, as measured under the described conditions.

Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Assay Buffer: 0.1 M Sodium Acetate, pH 4.5
 - Recombinant Mouse Lysosomal alpha-Glucosidase/GAA (rmGAA) (Catalog # 11400-GH)
 - Substrate: Starch from potato, 2% (w/v) stock in deionized water
 - Stop Solution: 4.4 mM Dinitrosalicylic Acid, 1 M Potassium Tartrate, 0.4 M Sodium Hydroxide in deionized water
 - Maltose Standard, 20 mM stock in deionized water
 - 96 well Clear Plate (Catalog # [DY990](#))
 - Plate Reader with Absorbance Read Capability

- Assay**
1. Dilute 20 mM Maltose standard by adding 200 μL of 20 mM Maltose Standard to 600 μL of Assay Buffer for a 5 mM stock. This is the first point of the standard curve.
 2. Prepare the standard curve by performing five one-half serial dilutions of the 5 mM Maltose stock in Assay Buffer. Make sure there are 400 μL in each tube for each point of the curve (remove 400 μL from the last point of the curve). Prepare one tube with only 400 μL of Assay Buffer for the curve blank. The standard curve has a range of 19.5 to 625 nmol per well.
 3. Dilute rmGAA to 32 μg/mL in Assay Buffer.
 4. Dilute 2% starch to 1.5% in Assay Buffer.
 5. Prepare reactions by combining 20 μL of diluted rmGAA with 380 μL of 1.5% starch (step 4). Include a control by combining 20 μL of Assay Buffer with 380 μL of 1.5% starch.
 6. Vortex, spin, and then incubate reactions, control, and standard curve at 37 °C for 1 hour.
 7. Add 400 μL of Stop Solution to all vials, including standard curve.
 8. Heat all vials at 95-100 °C for 6 minutes. Then, cool on ice. Tip: Use lid-locks to keep vials closed when heating.
 9. Load 250 μL of each dilution of the standard curve, reactions, and controls to empty wells in clear plate.
 10. Read plate at 546 nm (absorbance) in endpoint mode.
 11. Calculate specific activity:

$$\text{Specific Activity (pmol/min/}\mu\text{g)} = \frac{\text{Adjusted glucose produced* (nmol)} \times (1000 \text{ pmol/nmol})}{\text{Incubation time (min)} \times \text{amount of enzyme (}\mu\text{g)}}$$

*Derived from the maltose standard curve using linear or 4-parameter fitting and adjusted for Control.

- Final Assay Conditions**
- Per Well
- rmGAA: 0.2 μg
 - Starch: 0.71%

PREPARATION AND STORAGE


Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 6 months from date of receipt, -70 °C as supplied.
- 3 months, -70 °C under sterile conditions after opening.


DATA

Enzyme Activity



Recombinant Mouse Lysosomal α -Glucosidase His-tag Protein Enzyme Activity Diagram. Recombinant Mouse Lysosomal α -Glucosidase His-tag Protein, CF (Catalog # 11400-GH) hydrolyses both α -1,4- and α -1,6-glycosidic linkages on glycogen to release terminal glucose.

SDS-PAGE



Recombinant Mouse Lysosomal α -Glucosidase His-tag Protein SDS-PAGE. 2 μ g/lane of Recombinant Mouse Lysosomal α -Glucosidase His-tag Protein (Catalog # 11400-GH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 97-107 kDa, under reducing conditions.

BACKGROUND

Acid alpha-glucosidase (GAA) is an essential enzyme for the hydrolysis of glycogen α 1-4 and α 1,6-glycosidic linkages within the lysosome (1,2). GAA is a member of the glycoside hydrolase family GH31 and contains an N-terminal trefoil-P domain, a β -sheet domain, a catalytic barrel, and two C-terminal β -sheet domains (2). In addition to an active site and substrate binding domain, GAA has an additional reported secondary substrate-binding domain that may enhance the processivity of the enzyme (2). Mouse GAA has approximately 80% homology with human GAA. Defects in GAA cause glycogen storage disease II, also known as Pompe's disease, which is a rare autosomal recessive metabolic disorder that damages muscle and nerve cells due to accumulation of glycogen in the lysosome (3). Pompe disease occurs in babies, children, and adults who inherit a defective GAA gene and affects an estimated 5,000 to 10,000 people worldwide (4). Enzyme replacement therapy (ERT) is used to treat patients with Pompe disease and other lysosomal storage diseases (LSDs) (5, 6). Alternative therapeutic strategies such as pharmacological chaperone therapy (PCT) are being explored for use in concert with or independently for the potential to stabilize the target enzyme without impact to the catalytic activity (2, 7, 8).

References:

1. Hoefsloot, L.H. *et al.* (1988) EMBO J. **7**:1697.
2. Roig-Zamboni, V. *et al.* (2017) Nat. Commun. **8**:1111.
3. Wan, L. *et al.* (2008) J. Neurol. **255**:831.
4. Fukuda, T. *et al.* (2007) Curr. Neurol. Neurosci. Rep. **7**:71.
5. Van Gelder, C.M. *et al.* (2014) J. Inherit. Metab. Dis. In press.
6. Toscano, A. and B. Schoser. (2013) J. Neurol. **260**:951.
7. Porto, C. *et al.* (2012) Mol. Ther. **20**:2201.
8. Parenti, G. *et al.* (2015). Mol. Ther. **23**:1138.